Analysis of the key themes driving M&A activity reveals that artificial intelligence accounted for 7 pharmaceutical deals announced in Q1 2024, worth a total value of $345m. The $250m merger of Mediforum and Vision Sensing Acquisition and C2i Genomics was the industry’s largest disclosed deal. GlobalData’s Pharmaceuticals Industry Mergers and Acquisitions Deals by Top Themes report for Q1 2024 dissects the driving forces behind the M&A dynamics within the Pharma sector, offering essential insights into industry trends and transformations. Buy the report here.
In value terms, artificial intelligence-related deal activity increased by 667% in Q1 2024 compared with the previous quarter’s total of $45m and rose by 985% as compared to Q1 2023. Related deal volume decreased by 22% in Q1 2024 versus the previous quarter and was 133% higher than in Q1 2023.
The top-ranked financial advisors supporting these M&A deals in Q1 2024 were EF Hutton; Morgan Stanley; Norwich Capital with 1, 1, 1 deals respectively.
The top-ranked legal advisors supporting these M&A deals in Q1 2024 were Fenwick & West; Kirkland & Ellis; Loeb & Loeb with 1, 1, 1 deals respectively.
For further understanding of GlobalData's Pharmaceuticals Industry M&A Deals by Top Themes in Q1 2024 – Thematic Intelligence, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.